In a video interview from the recent American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, Brian Chapin, MD, discussed emerging research that demonstrated the ability of the positron emission tomography (PET) agent 18F-rhPSMA-7.3 to diagnose distant M1 lesions prior to surgery for patients with intermediate to high-risk prostate cancer.
Conventional imaging can be limited in the detection of metastatic lesions associated with prostate cancer. Specificity rates for computed tomography (CT) are “reportedly all over the map,” ranging from 40 to 60 percent, pointed out Brian Chapin, MD, in a video interview from the recent American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) symposium.
“When there is lymph node involvement … , the lymph nodes themselves can be small and the deposits within those lymph nodes can be as small as 1 to 3 mm in size sometimes so it’s really hard to identify those with a conventional imaging approach,” explained Dr. Chapin, an associate professor, director of clinical research and fellowship program director in the Department of Urology within the Division of Surgery at the University of Texas MD Anderson Cancer Center in Houston.
However, in recent research presented at the ASCO GU symposium, Dr. Chapin and colleagues found the use of the radiopharmaceutical agent 18F-rhPSMA-7.3 (Blue Earth Diagnostics/Bracco Imaging) with positron emission tomography (PET) led to verified detection of distant metastatic lesions in 10 to 15 percent of 335 patients with newly diagnosed intermediate or high-risk prostate cancer.
“One in 10 patients that we had planned to bring to the operating room with presumed localized prostate cancer indeed had metastatic disease, which is quite substantial, especially when you’re looking at a population of men who had (negative conventional imaging with CT, MRI and bone scan),” emphasized Dr. Chapin. “Those were all negative and you’re identifying metastatic disease in one in 10 patients. That is pretty substantial because that can change our clinical decision-making in how we treat patients.”
(Editor’s note: For related content, see “Study Assesses PET Agent for Detecting Pelvic Lymph Node Metastases in Patients with Prostate Cancer,” “Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?” and “Is PSMA PET/CT More Beneficial than Bone Scintigraphy in Detecting Bone Lesions in Cases of High-Risk Prostate Cancer?”)
For more insights from Dr. Chapin, watch the video below.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
Study: Black Patients Less Likely Than Others to Receive MRI Assessment of Cognitive Impairment
November 27th 2023In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.